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SUMMARY
Objective. Interactions between SARS-CoV-2 and pharyngeal associated lymphoid tissue 
are thought to influence the manifestations of COVID-19. We aimed to determine whether 
a previous history of tonsillectomy, as a surrogate indicator of a dysfunctional pharyngeal 
associated lymphoid tissue, could predict the presentation and course of COVID-19.
Methods. Multicentric cross-sectional observational study involving seven hospitals in 
Northern and Central Italy. Data on the clinical course and signs and symptoms of the in-
fection were collected from 779 adults who tested positive for SARS-CoV-2, and analysed 
in relation to previous tonsillectomy, together with demographic and anamnestic data.
Results. Patients with previous tonsillectomy showed a greater risk of fever, temperature 
higher than 39°C, chills and malaise. No significant differences in hospital admissions were 
found.
Conclusions. A previous history of tonsillectomy, as a surrogate indicator of immunologi-
cal dysfunction of the pharyngeal associated lymphoid tissue, could predict a more intense 
systemic manifestation of COVID-19. These results could provide a simple clinical marker 
to discriminate suspected carriers and to delineate more precise prognostic models.
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RIASSUNTO 
Obiettivo. Si ritiene che le manifestazioni dell’infezione da SARS-CoV-2 siano influenzate 
dalle interazioni tra il virus e il tessuto linfatico associato alla faringe. Obiettivo di questo 
studio è determinare se una pregressa tonsillectomia, come indicatore surrogato di disfun-
zione immunologica faringea, possa predire la presentazione e il decorso della COVID-19.
Metodi. Studio multicentrico trasversale osservazionale coinvolgente 7 centri italiani. Sono 
stati raccolti i dati su decorso, segni e sintomi dell’infezione da 779 adulti positivi al SARS-
CoV-2, e analizzati in relazione a pregressa tonsillectomia, dati demografici e anamnestici.
Risultati. I pazienti con pregressa tonsillectomia hanno un maggior rischio di sviluppare 
febbre, raggiungere temperature oltre i 39°C, brividi e malessere generalizzato. Non si 
riscontrano differenze nel tasso di ospedalizzazione.
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Introduction
Coronavirus disease 2019 (COVID-19), caused by the 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), has shown a wide variety of manifestations, rang-
ing from asymptomatic infection to critical respiratory 
failure  1,2. Fever, cough, shortness of breath and sudden 
onset of smell and taste deficiency are frequently reported, 
alongside gastrointestinal disturbances and non-specific 
complaints such as myalgia and malaise 1. Various risk fac-
tors have been debated to influence symptom severity and 
prognosis, such as sex, coexisting chronic disorders and 
tobacco use; however, the interindividual variability and 
susceptibility are not fully understood 3,4.
The role of the pharyngeal microenvironment in the trans-
mission, modulation, and clinical progression of SARS-
CoV-2 infection has been receiving growing attention  5. 
SARS-CoV-2 is known to enter the host mucosa via the an-
giotensin converting enzyme 2 6, which it uses to colonise 
the upper airway tract in addition to other target organs 7. 
The pharyngeal surfaces of the upper airways are charac-
terised by secondary lymphoid organs and mucosal-asso-
ciated lymphoid tissue (MALT), which form a morpho-
functional immunologic unit known as “Waldeyer’s ring”.
Waldeyer’s ring is a key structure in stimulating locore-
gional immune response and tolerance towards infec-
tive stimuli. In this lymphoid tissue, foreign antigens are 
processed and presented to naïve lymphocytes through a 
complex network involving dendritic, T-helper and B-cells, 
eventually forming high affinity colonies that differentiate 
in activated plasma cells and memory cells. This process 
leads to specific IgA production, which can be found all 
along the upper airway tract mucosa and secretions; on the 
other hand, the memory B-cells generated migrate to other 
lymphoid organs, such as the spleen and local and distant 
lymph nodes 8.
An intrinsic incapability to elicit and regulate an appropri-
ate immune response is thought to be a key element in the 
pathogenesis of recurrent tonsillitis; the resulting chronic 
inflammatory state further jeopardises the mutual interac-
tion between the locoregional immune cells and with for-
eign pathogens, leading to a vicious cycle that ends with 
failure to form an effective barrier against infective agents 9. 
Tonsillectomy represents one of the most frequently per-
formed operations by otolaryngologists and surgeons, and 
constitutes the mainstay treatment for chronic or recurrent 
tonsillitis that do not benefit from medical therapy alone 10.
It has long been debated if tonsillectomy might interfere 
with host immune response and susceptibility to airborne 
infections. The first studies appeared in the early 1970s, 
when Ogra showed a reduced level of IgA in nasopharyn-
geal secretions and a diminished local immune response 
to oral poliovirus vaccine in children who had undergone 
adeno-tonsillectomy  11. Since then, several reports have 
been published, with non-univocal conclusions: if removal 
of the palatine tonsils alone does not seem to considerably 
influence humoral and cellular systemic immunity 12, their 
importance in both promoting and effecting the local in-
flammatory response and production of antibody-secreting 
cells is better outlined, with the latter spreading throughout 
the upper airway mucosa and memory cells migrating to 
regional and distant lymph nodes and secondary lymphoid 
organs 13. This key role decreases with age, but residual ac-
tivity has been found in patients older than 80 years; chron-
ic and recurrent inflammation are crucial in accelerating the 
decay of immune function 8.
If the role of pharyngeal microenvironment in COVID-19 
pathophysiology and course is of great research interest, its 
usefulness in daily practice requires clinical markers that 
could provide information on its status. In the hypothesis 
that a previous tonsillectomy could reflect a locoregional 
chronic inflammatory state as a result of an impaired im-
munological Waldeyer’s ring activity, we wanted to assess 
its possible role as a predictor of interindividual variability 
in host response to SARS-CoV-2 infection.
Materials and methods
Study design
We conducted this multicentric observational cross-sec-
tional study at 7 centres from Northern and Central Italy, 
areas with a high prevalence of confirmed cases at the time 
of the study (University Hospital of Trieste; University 
Hospital of Modena; Treviso Regional Hospital; IRCCS 
San Raffaele Scientific Institute, Milan; Niguarda Hospital, 
Milan; Hospital of Chioggia; Hospital of Fano) 14.
The study was approved by the Ethics Committee of the 
Friuli Venezia Giulia Region on June 16th, 2020 (CEUR-
2020-Os-156), and informed consent was obtained verbally 
for telephone interviews. The authors received no funding 
for the study.
Conclusioni. Il dato anamnestico di pregressa tonsillectomia, come indicatore di disfunzione immunologica faringea, può predire una mani-
festazione sistemica più intensa nei pazienti affetti da COVID-19. Questi risultati possono fornire un marker clinico semplice per discriminare 
sospetti portatori del virus e delineare modelli prognostici più accurati. 
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Patients
Adults (≥ 18 years) assessed at the participant hospitals 
between February 25th and May 20th, 2020, were included 
if they tested positive for SARS-CoV-2 RNA by polymer-
ase chain reaction on nasopharyngeal and throat swabs 
performed according to the World Health Organization 
recommendation 15. Criteria for exclusion were a diagno-
sis of cognitive impairment reported by the patient or a 
caregiver, and inability to answer one or more questions 
in the questionnaire.
Data collection
Data were collected from clinical charts compiled dur-
ing hospitalisation, during evaluation in the emergency 
room, at the moment of the pharyngeal swab testing and 
updated with subsequent telephonic monitoring, which 
was active during the state of emergency for the treated-
at-home patients and performed by trained medical per-
sonnel. Any missing information was eventually filled in 
by trained medical personnel who recalled the patients, 
assessing missing demographic and anamnestic data and 
possible common signs and symptoms of COVID-19 that 
were not reported or updated in the charts. The examined 
items were arbitrarily chosen based on the most frequent 
COVID-19-associated comorbidities, signs and symptoms, 
as reported by the literature at the time of the study design. 
Patients were considered affected by a coexisting disorder 
if they had been previously diagnosed and if (one of the fol-
lowing): i) required or had required pharmacological thera-
py; ii) led to a hospital admission; iii) treated with surgery 
or with chemotherapy, radiotherapy, biological therapy, or 
other oncological therapies. 
Signs and symptoms were classified as COVID-19-related 
if they appeared de novo or as a worsening of a chronic 
symptom within a period of 14 days before or after the pos-
itive result of the microbiological test. Those who did not 
develop new signs, symptoms, or worsening of a chronic 
symptom within this period were classed as “asympto-
matic”. Interviews were conducted at least 20 days after 
the microbiological test in order to reduce the risk of false 
asymptomatic cases in pre-symptomatic patients.
Outcomes 
The primary outcome was to determine differences in 
the prevalence of the investigated signs and symptoms 
among patients who had undergone tonsillectomy and 
patients who had not. Risk to develop a sign or a symp-
tom according to previous history of tonsillectomy was 
assessed in the multivariate analysis, together with pa-
tient characteristics.
Secondary outcome was risk estimation of hospital admis-
sion according to previous history of tonsillectomy. Patient 
characteristics hypothesised to influence outcomes, togeth-
er with previous tonsillectomy, were included in multivari-
ate analysis.
Sample size calculation
Sample size was determined considering patients with a 
previous tonsillectomy as the case group and fever as the 
event, assuming that fever is highly common among pa-
tients with COVID-19 and, being a sign rather than a symp-
tom, is less prone to patient subjective interpretation. Given 
a population with a supposed prevalence of 25% of tonsil-
lectomies, hypothesising a prevalence of fever of 70% in 
the group who had undergone tonsillectomy and of 60% 
in the group who had not, it was necessary to enroll 585 
patients, with α = 5% and power (1– b) = 95%.
Statistical analysis
Continuous variables were expressed as means and stand-
ard deviation or medians and interquartile ranges (IQR), 
according to data distribution determined with the Shapiro-
Wilk test. Categorical variables were summarised as counts 
and percentages. No imputation was made for missing data.
In univariate analysis, Fisher’s exact test was performed for 
categorical variables, whereas the Mann-Whitney U test 
was performed for continuous variables. Logistic regres-
sion was performed in multivariate analysis; results of mul-
tivariate analysis are reported as odds ratio (OR) and 95% 
confidence interval (95% CI). 
P values <  0.05 (two-sided) were considered statistically 
significant. Statistical analyses were performed using SPSS 
Version 26 (IBM Corp., Armonk, NY, USA).
Results
Patients
We recruited 779 patients. Table I shows the distribution 
of patient characteristics in detail, overall and in relation to 
previous tonsillectomy. Median age was 50.0 ± 20.1 years, 
and 54.2% of patients were female. Active smokers ac-
counted for 10.5%, and former smokers and non-smokers 
for 21.6% and 67.9%, respectively. About one-third of the 
population had at least one comorbidity (38.5%), with a 
higher prevalence of chronic cardiovascular disease or hy-
pertension (15.9%) and obesity (13.9%).
Tonsillectomy had been performed on 27.3% of patients. 
Tonsillectomised patients appeared to be older and with a 
higher prevalence of associated disorders than the non-ton-
sillectomised subgroup. No difference in sex distribution 
was recorded among the two groups.
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Tonsillectomy and SARS-CoV-2 infection
The distribution of the examined signs and symptoms ac-
cording to previous tonsillectomy and related univariate 
analysis are summarised in Table II. Tonsillectomised pa-
tients showed a significantly higher prevalence of fever, 
temperature greater than 39°C and shortness of breath, with 
a lower rate of nasal congestion and myalgia compared to 
patients who did not undergo tonsillectomy.
Table III summarises the results of multivariate analysis, 
showing the signs and symptoms at augmented risk to be 
developed in case of previous tonsillectomy. Patients with 
a previous history of tonsillectomy showed greater risk to 
report fever and to reach temperatures higher than 39°C. 
An increased risk for chills and malaise was also observed. 
The association with nasal congestion was lost.
Tonsillectomised patients did not show an increased risk to 
develop the other investigated signs and symptoms: cough 
(OR 1.06, 95% CI 0.69-1.63, p = 0.78), shortness of breath 
(OR 1.35, 95% CI 0.86-2.11, p = 0.19, confusion (OR 1.58, 
95% CI 0.87-2.90, p  =  0.14), rhinorrhoea (OR 0.99, 95% 
CI 0.58-1.70, p = 0.98), nasal congestion (OR 0.68, 95% CI 
0.41-1.13, p = 0.14), sore throat (OR 1.60, 95% CI 0.98-2.62, 
p = 0.06), myalgia (OR 0.93, 95% CI 0.61-1.43, p = 0.76), 
dizziness (OR 1.12, 95% CI 0.57-2.21, p = 0.75), headache 
(OR 1.12, 95% CI 0.73-1.72, p = 0.60), nausea (OR 0.62, 
95% CI 0.33-1.14, p = 0.12), diarrhoea (OR 1.16, 95% CI 
0.75-1.80, p = 0.51). Odds to have an asymptomatic course 
did not differ between tonsillectomised and non-tonsillecto-
mised patients (OR 1.26, 95% CI 0.53-3.00, p = 0.60). 
Tonsillectomy and risk of hospitalisation
While previous tonsillectomy was more prevalent among 
patients admitted to hospital, tonsillectomised patients did 
not show an increased risk for admission at the multivariate 
analysis (Tab. IV).
Discussion
In our study, we wanted to explore the possibility that a 
previous tonsillectomy, as an indicator of chronic tonsillitis 
and possibly of immunological dysfunction of the Waldey-
er’s ring, could reflect the underlying characteristic of the 
Table I. Clinical characteristics of study patients.
Characteristic All patients Tonsillectomy





Age - median (IQR) 50.0 (20.1) 55.2 (14.0) 48.0 (19.2) < 0.001***
Sex
Male sex 357 (45.8) 106 (49.8) 251 (44.3) 0.20
Female sex 422 (54.2) 107 (50.2) 315 (55.7)
Smoking history
Current 82 (10.5) 21 (9.9) 61 (10.8) 0.79
Former 168 (21.6) 47 (22.1) 121 (21.4) 0.85
Never 529 (67.9) 145 (68.1) 384 (67.8) > 0.99
Current alcohol consumption 267 (34.3) 77 (36.2) 190 (33.6) 0.50
Presence of any allergy 271 (34.8) 77 (36.2) 194 (34.3) 0.67
BMI – median (IQR) 25.0 (5.3) 25.1 (5.6) 24.9 (5.2) 0.13
Any coexisting disorder 300 (38.5) 106 (49.8) 194 (34.3) < 0.001***
Obesity 108 (13.9) 36 (16.9) 72 (12.7) 0.13
Chronic pneumopathy 36 (4.6) 13 (6.1) 23 (4.1) 0.25
Chronic cardiovascular disease or hypertension 124 (15.9) 50 (23.5) 74 (13.1) 0.001***
Diabetes 44 (5.6) 21 (9.9) 23 (4.1) 0.003**
Immunodeficiency 3 (0.4) 1 (0.5) 2 (0.4) > 0.99
Autoimmune disease 60 (7.7) 18 (8.5) 42 (7.4) 0.65
Chronic renal disease 11 (1.4) 5 (2.3) 6 (1.1) 0.18
Hepatopathy 24 (3.1) 10 (4.7) 14 (2.5) 0.16
Cancer (current or previous) 21 (2.7) 6 (2.8) 15 (2.7) > 0.99
Column percentages are reported in brackets for categorical variables. p-values refer to the univariate analysis (Fisher’s exact test, Mann-Whitney’s U test). IQR: interquartile range. 
BMI: body mass index. * = p < 0.05. ** = p < 0.01. *** = p < 0.001.
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patient pharyngeal MALT and related COVID-19 manifes-
tations. 
In our population, tonsillectomised patients showed an in-
creased risk of developing fever and temperatures higher 
than 39°C, along with malaise and chills. It is plausible that 
malaise and chills were consequences of the fever and its 
intensity, reflecting a more intense systemic involvement. 
Patients with previous history of tonsillectomy were older 
and with more coexisting disorders than those who did not 
receive the operation. However, even accounting for these 
possible confounding factors in the multivariate logistic 
regression, tonsillectomised patients still showed a greater 
risk to express a more intense systemic response to the vi-
rus. In the multivariate analysis, p-values associated with 
augmented risk to develop fever and temperatures higher 
than 39°C were far below the value of 0.05 set for signifi-
cance (p = 0.003 and p < 0.001, respectively), bypassing 
the possible over-powering effect of our large sample and 
giving strength to our hypothesis.
As mentioned above, tonsillectomy itself is probably an in-
dicator rather than the cause of a decreased Waldeyer’s ring 
immune function; its activity of defense and inflammatory 
regulation is furtherly worsened by chronic infections that 
eventually lead to a vicious cycle and to surgical removal 8. 
Significant differences have been demonstrated between 
frequently infected palatine tonsils compared to healthy 
controls, such as a different composition of the antigen-
presenting cell (APC) population, a reduced capability in 
regulating the inflammatory response and decreased IgA 
and IgM production 13.
Frequently infected tonsils show an abnormal distribution 
of activated dendritic cells (DCs), the most efficient APC, 
which appear superficially concentrated on the lympho-ep-
ithelium in addition to the interfollicular T-cell areas: this 
suggests an increased production of inflammatory media-
tors and chemotactic dysregulation  16-18. DCs also medi-
ate B-/T-cell interaction, which results in the selection 
of specific activated B-cells, memory B-cells and anti-
inflammatory T-cell-derived cytokines such as IL-10 19: 
impairment of the role of DC could undermine these es-
sential immune functions in patients with chronic tonsil-
litis 13. 
Moreover, tonsils subjected to chronic inflammation show 
a reduced production of anti-inflammatory cytokines and a 
lowered tolerance to viral infections compared to isolated 
hyperplasia. In a study by Mikola et al., tonsillar mRNA 
expression of IL-37, a fundamental inhibitor of innate im-
munity and inflammatory cytokines, appeared to be di-
minished in the chronic tonsillitis group when adjusted for 
age  20. Additionally, B-regulatory cells suppress effector 
Table II. Distribution of COVID-19-related signs and symptoms.
Signs and symptoms All patients Tonsillectomy





Asymptomatic 46 (5.9) 13 (6.1) 33 (5.8) 0.87
Fever 508 (65.2) 156 (73.2) 352 (62.2) 0.004**
T > 39°C 82 (10.5) 36 (16.9) 46 (8.1) 0.001**
Cough 411 (52.8) 113 (53.1) 298 (52.7) 0.94
Shortness of breath 239 (30.7) 80 (37.6) 159 (28.1) 0.01*
Chills 255 (32.7) 76 (35.7) 179 (31.6) 0.30
Malaise 423 (54.3) 124 (58.2) 299 (52.8) 0.20
Confusion 89 (11.4) 30 (14.1) 59 (10.4) 0.17
Rhinorrhoea 150 (19.3) 37 (17.4) 113 (20.0) 0.48
Nasal congestion 193 (24.8) 40 (18.8) 153 (27.0) 0.02*
Sore throat 180 (23.1) 53 (24.9) 127 (22.4) 0.51
Myalgia 385 (49.4) 92 (43.2) 293 (51.8) 0.04*
Dizziness 78 (10.0) 19 (8.9) 59 (10.4) 0.59
Headache 343 (44.0) 87 (40.8) 256 (45.2) 0.29
Nausea 126 (16.2) 29 (13.6) 97 (17.1) 0.28
Diarrhoea 260 (33.4) 77 (36.2) 183 (32.3) 0.35
Smell disturbance 446 (57.3) 113 (53.1) 333 (58.8) 0.17
Taste disturbance 446 (57.3) 113 (53.1) 333 (58.8) 0.17
Column percentages are reported in brackets for categorical variables. p-values refer to the univariate analysis (Fisher’s exact test). * = p < 0.05. ** = p < 0.01. *** = p < 0.001.
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T-cells and other lymphocytes via production of IL-10, IL-
35 and TGF-β, and they are involved in supporting immu-
nological tolerance. These cells are distributed among all 
human lymphoid tissues, including the palatine and naso-
pharyngeal tonsils 21.
Finally, the impaired secretion of IgM and IgA finds its 
molecular counterpart in a reduced cytoplasmatic expres-
sion of the J-chain, a peptide implied in the formation of 
the cited polymeric immunoglobulins, among youngsters 
with recurrent tonsillitis 22. In the possibility of routine ap-
plication of a rapid salivary SARS-CoV-2 screening test, 
it might be necessary to take into account the role of the 
tonsils in mediating the production of secretive antibodies 
and local clearance of the virus 23.
All these features, together with the components of the in-
nate immunity hosted by pharyngeal MALT, are involved 
in the response against viruses and have a role in the inter-
individual variability of the manifestation and transmission 
of COVID-19 5, as our findings appear to support.
For what concerns the severity and clinical course of the 
disease, assuming hospital admission as a surrogate indi-
cator of severity, no significant differences emerged be-
tween tonsillectomised and non-tonsillectomised patients. 
This finding, representing the secondary outcome of our 
Table III. COVID-19-related signs and symptoms affected by history of previous tonsillectomy.






































































































































































Results of the multivariate logistic regression. Odds ratio (95% confidence interval) and p-values for each variable are reported. * = p < 0.05. ** = p < 0.01. *** = p < 0.001.
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work, may have been partially biased by the impossibility 
to retrieve accurate data from those who died, as well as 
the lack of other surrogate indicators such as hospitalisa-
tion time, complication rate and the small percentage of 
asymptomatic subjects. A more inclusive cohort account-
ing for all the above-mentioned biases and possible in-
dicators of severity and complications may be necessary 
to specifically clarify the possible role of Waldeyer’s ring 
status on the global severity and clinical course of the dis-
ease.
Our results seem to corroborate a potentially independ-
ent role of pharyngeal-associated lymphoid organs in the 
host response to SARS-CoV-2 infection. The fundamental 
importance of these organs in patrolling the upper airways 
against SARS-CoV-2 and other infective agents has been 
widely recognised  5. The higher prevalence of systemic 
signs and symptoms in the tonsillectomised patients in our 
cohort can be explained hypothesising that intrinsic impair-
ment of the pharyngeal lymphoid tissues led to both chronic 
tonsillitis and tonsillectomy in the past, and now the same 
dysfunction could be responsible for an altered response 
to SARS-CoV-2. An uncontrolled inflammatory reaction 
to the virus, mediated by a dysfunctional Waldeyer’s ring, 
could have led to fever, higher temperatures and associated 
symptoms. From this perspective, previous tonsillectomy 
as an indicator of an impaired immunological activity of 
pharyngeal MALT could be regarded as a predictor of an 
altered host response to SARS-CoV-2 infection. Vice-ver-
sa, people with a functional Waldeyer’s ring could develop 
more subtle and less intense symptoms, possibly leading to 
lack of identification of viral carriers.
As tonsillectomy is frequently performed and has a high 
prevalence in general population, this anamnestic informa-
tion may take on potential relevance in the context of the 
COVID-19 pandemic  10. If these findings are confirmed 
by further studies, investigating history of previous tonsil-
Table IV. Distribution of patient characteristics according to clinical course and risk of hospital admission.





p OR (95% CI) p
Age 48.0 (19.0) 62.3 (19.1) < 0.001*** 1.07 (1.05-1.09) < 0.001***
Sex 
Male 283 (42.4) 74 (66.7) < 0.001*** 2.33 (1.37-3.98) 0.002**
Female 385 (57.6) 37 (33.3) Ref -
Smoking history - 0.01*
Current 79 (11.8) 3 (2.7) 0.002** 0.26 (0.07-0.92) 0.04*
Former 126 (18.9) 42 (37.8)  < 0.001*** 1.62 (0.97-2.69) 0.07
Never 463 (69.3) 66 (59.5) 0.05 Ref -
Current alcohol consumption 208 (31.1) 59 (53.2) < 0.001*** 1.37 (0.83-2.24) 0.22
Presence of any allergy 243 (36.4) 28 (25.2) 0.02* 0.68 (0.40-1.14) 0.15
BMI 24.7 (5.2) 26.8 (5.2) < 0.001*** 1.01 (0.93-1.10) 0.78
Any coexisting disorder 232 (34.7) 68 (61.3) < 0.001*** 2.43 (1.12-5.29) 0.03*
Obesity 85 (12.7) 23 (20.7) 0.04* 1.07 (0.40-2.87) 0.89
Chronic pneumopathy 29 (4.3) 7 (6.3) 0.33 1.10 (0.38-3.18) 0.86
Chronic cardiovascular disease or 
hypertension
96 (14.4) 28 (25.2) 0.007** 0.42 (0.21-0.85) 0.02*
Diabetes 33 (4.9) 11 (9.9) 0.05 0.47 (0.19-1.20) 0.12
Immunodeficiency 3 (0.4) 0 (0.0%) 1.00 0.00 (0.00-.) > 0.99
Autoimmune disease 51 (7.6) 9 (8.1) 0.85 1.03 (0.40-2.61) 0.96
Chronic renal disease 6 (0.9) 5 (4.5) 0.01* 4.99 (1.05-23.83) 0.04*
Hepatopathy 18 (2.7) 6 (5.4) 0.14 0.79 (0.25-2.54) 0.69
Cancer (current or previous) 12 (1.8) 9 (8.1) 0.001** 1.50 (0.48-4.71) 0.49
Tonsillectomy 171 (25.6) 42 (37.8) 0.01* 1.38 (0.75-2.53) 0.30
Counts (column percentages) are reported in brackets for categorical variables, medians (interquartile range) are reported for continuous variables. Results of the univariate (Fisher’s 
exact test, Mann-Whitney’s U test) and multivariate (logistic regression) analysis are reported, with related p-values. BMI: Body Mass Index. OR: odds ratio. 95% CI: 95% confidence 
interval. * = p < 0.05. ** = p < 0.01. *** = p < 0.001.
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lectomy could help physicians to characterise the clinical 
manifestations in patients with suspected SARS-CoV-2 in-
fection: knowing that non-tonsillectomised patients might 
show less symptoms and pass unnoticed, this could be a 
relevant information to correctly refer for screening tests 
wherever these are administered on the basis of the report-
ed symptomatology 24. 
The main limitation of this study is represented by the ab-
sence of deceased patients in our cohort, which may have 
affected the analysis of disease severity according to the 
variables investigated. This was unavoidable because of 
the impossibility to retrieve complete information about 
previous operations, coexisting disorders and COVID-
19-related symptoms. However, it was deemed acceptable 
at the time of the study design given the small percentage 
of deaths in relation to the total number of cases in Italy 
during the recruitment phase, probably with low effects on 
the outcomes 25.
Another limitation may be the self-reported nature of the 
information on coexisting disorders. We tried to limit inac-
curacies by relying on objective data such as pharmacolog-
ical history and diagnosis made during hospital admission. 
The main strength of this work is the completeness of the 
data analysed, prospective collection of information and 
lack of assumptions for missing data.
Conclusions
According to our results, patients with SARS-CoV-2 infec-
tion and previous tonsillectomy might be more likely to 
develop a more intense and systemic response, with fever, 
higher temperatures, chills and malaise. This may reflect 
subtle differences in the immunological response to the 
virus caused by impaired pharyngeal MALT functional-
ity. Although non-conclusive, these findings may shed new 
light on the pathophysiology of COVID-19 and support 
current evidence on the role of the pharyngeal microenvi-
ronment on the disease course. If confirmed, these results 
could help discriminate suspected SARS-CoV-2 carriers, 
providing indications for the screening test knowing the 
higher risk of a subtler manifestation in non-tonsillecto-
mised patients, and potentially delineating more precise 
prognostic models.
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